Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

Short Title: CCTG-CO32

Enrollment Status: Recruiting

NCT #: NCT06205485

Specialty Area: Oncology

Condition Studied: Rectal Adenocarcinoma

Age Groups: Adult; Older Adult

Phase: III

Study Information

Summary / Purpose

To determine if chemotherapy alone can achieve similar tumor response and better quality of life compared to the standard chemoradiotherapy approach.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with well to moderately differentiated rectal adenocarcinoma
Tumor must be mid- to low-lying and eligible for transanal excision (surgical removal)
MRI stage cT1 not eligible for transanal surgery alone, or cT2
No evidence of nodal or distant metastasis (cN0, M0)
Medically fit for surgery

What's Involved

Participation in the study will include:

Either chemotherapy alone or chemoradiation before surgery
Transanal endoscopic surgery (TES)
Regular follow-up with MRI and endoscopy to monitor response to treatment
Blood samples to check your health and how the treatment is working
Questionnaires

Principal Investigator

Garrett Green, MD

Radiation Oncology

A Member of

(775) 982–5638

William N. Pennington Cancer Institute

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06205485

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews